---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-019717"
form_type: "8-K"
ticker: "CAPR"
cik: "0001133869"
company_name: "CAPRICOR THERAPEUTICS, INC."
filed_at: "2023-12-11T23:59:59+00:00"
generated_at: "2026-06-07T14:42:15.011101+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Capricor Phase 3 HOPE-3 trial of CAP-1002 in DMD passes interim futility analysis; milestone payment triggered

## Summary
- Positive interim futility analysis from DSMB; trial to continue as planned.
- Triggers first milestone payment under U.S. agreement with Nippon Shinyaku.
- HOPE-3 Cohort A enrollment complete; topline data expected Q4 2024.
- Company plans to request FDA meeting in Q1 2024 for expedited approval pathways.
- Cohort B enrollment initiated; ~102 subjects total across both cohorts.

## SEC filing metadata
- accession: 0001558370-23-019717
- form_type: 8-K
- ticker: CAPR
- cik: 0001133869
- company_name: CAPRICOR THERAPEUTICS, INC.
- filed_at: 2023-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133869/000155837023019717/0001558370-23-019717-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133869/000155837023019717/capr-20231211x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-019717
- JSON: https://secwatch.observer/filing/0001558370-23-019717.json
- Plain text: https://secwatch.observer/filing/0001558370-23-019717.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.